comprehensive -WSS

comprehensive

author：explore 2025-10-01 05:39:57 - browse：5723

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

WSS

Assistant physicians can help address the primary care shortage

People with substance use disorder deserve online privacy

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

David Liu startup to focus on CRISPR delivery

A daunting task: navigating dual Medicare, Medicaid eligibility

Morphosys mixed study results for blood cancer drug

leisure time

comprehensive

hotspot

Psychedelics group wrestles with new pharma identity

Neurocrine congenital adrenal hyperplasia trial succeeds

Affirmative action in medical school literally saved lives

Poor hospice wound care hurts patients and families

The high cost of giving birth even with insurance

Why the drug industry's warnings on the IRA's impact fall short

DIEP, the 'gold standard' of breast reconstruction, is under threat

Assistant physicians can help address the primary care shortage

23andMe had bad news about my health. I wish a person had delivered it

How the messy conversation about Dolly changed bioethics

Wikipedia

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Neurocrine congenital adrenal hyperplasia trial succeeds

Free Covid tests will again be offered to all U.S. households

NYU radiologists take on the challenge of expensive MRI machines

Information blocking fines are now fair game in health care

Wegovy, Zepbound and weight loss drugs that preserve muscle

explore

hotspot

hotspot

leisure time